Over decades, substantial progress has been achieved in understanding the pathogenesis of proteinuria in diabetic kidney disease (DKD), biomarkers for DKD screening, diagnosis, and prognosis, as well as novel hypoglycemia agents in clinical trials, thereby rendering more attention focused on the role of renal tubules in DKD. Previous studies have demonstrated that morphological and functional changes in renal tubules are highly involved in the occurrence and development of DKD. Novel tubular biomarkers have shown some clinical importance. However, there are many challenges to transition into personalized diagnosis and guidance for individual therapy in clinical practice. Large-scale clinical trials suggested the clinical relevance of increa...
The prevalence of diabetic nephropathy has tremendously increased with the relentless rise in the in...
Purpose of Review Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have emerged as a promising dr...
Background: Sodium-glucose cotransport protein 2 (SGLT2) inhibitors, a new type of glucose-lowering ...
The prevalence of diabetes is increasing worldwide, and one of the most important complications, dia...
Although diabetic kidney disease (DKD) remains the leading cause of end-stage kidney disease eventua...
Diabetes mellitus (DM) is the major cause of end-stage renal disease (ESRD) globally, and novel trea...
As the prevalence of diabetic kidney disease (DKD) continues to rise, so does the need for a novel t...
Background. Tubulointerstitial injury is both a key feature of diabetic nephropathy and an important...
Diabetes mellitus (DM) is the major cause of end-stage renal disease (ESRD) globally, and novel trea...
Since the 1930s when Kimmelstiel and Wilson first described the classic nodular glomerulosclerosis l...
Diabetic kidney disease (DKD) is a major microvascular complication of diabetes and a common cause o...
Diabetic kidney disease (DKD) is a major microvascular complication of diabetes and a common cause o...
AbstractGlucose filtered by kidneys is reabsorbed into the proximal tubule through the sodium-couple...
Purpose of Review Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have emerged as a promising dr...
Purpose of Review Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have emerged as a promising dr...
The prevalence of diabetic nephropathy has tremendously increased with the relentless rise in the in...
Purpose of Review Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have emerged as a promising dr...
Background: Sodium-glucose cotransport protein 2 (SGLT2) inhibitors, a new type of glucose-lowering ...
The prevalence of diabetes is increasing worldwide, and one of the most important complications, dia...
Although diabetic kidney disease (DKD) remains the leading cause of end-stage kidney disease eventua...
Diabetes mellitus (DM) is the major cause of end-stage renal disease (ESRD) globally, and novel trea...
As the prevalence of diabetic kidney disease (DKD) continues to rise, so does the need for a novel t...
Background. Tubulointerstitial injury is both a key feature of diabetic nephropathy and an important...
Diabetes mellitus (DM) is the major cause of end-stage renal disease (ESRD) globally, and novel trea...
Since the 1930s when Kimmelstiel and Wilson first described the classic nodular glomerulosclerosis l...
Diabetic kidney disease (DKD) is a major microvascular complication of diabetes and a common cause o...
Diabetic kidney disease (DKD) is a major microvascular complication of diabetes and a common cause o...
AbstractGlucose filtered by kidneys is reabsorbed into the proximal tubule through the sodium-couple...
Purpose of Review Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have emerged as a promising dr...
Purpose of Review Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have emerged as a promising dr...
The prevalence of diabetic nephropathy has tremendously increased with the relentless rise in the in...
Purpose of Review Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have emerged as a promising dr...
Background: Sodium-glucose cotransport protein 2 (SGLT2) inhibitors, a new type of glucose-lowering ...